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Background
Relative measures quantify the effect of an intervention
but are difficult to translate into practice. Clinicians
prefer absolute measures like the number needed to
treat (NNT). We demonstrate a novel approach for
reporting treatment effect across an ordered outcome
where higher scores indicate worse functional outcome.
We used the first and the third International Stroke
Trials (IST-1 and IST-3) as case studies.
Methods
A two by ‘K’ table of treatment versus control over an
ordinal outcome (with K levels) can be modelled as a
multinomial distribution and the probabilities for each
cell estimated. We calculated the number of score
points gained per 1000 patients treated and estimated
the 95% CI using bootstrap methods. Negative values
indicate benefit with treatment whilst positive values
indicate harm with treatment. We categorised patients
into groups of poor functional outcome using prediction
models (low (≤35%), medium (35 to 56%), and high
(>56%)) and calculated the net gain in functional out-
come within each stratum.
Results
The gain in Oxford Handicap Score (OHS) points per
1000 treated in IST-3 for low risk was 14 (95% CI -199
to 240), for medium risk -295 (95%CI -566 to -19) and
for high risk -230 (95%CI -396 to -65). The gain in a
four level functional outcome score in IST-1 for low risk
was -112 (95% CI -214 to -9), for medium risk -42 (95%
CI -95 to 12) and for high risk -29 (95% CI -59 to 2).
Conclusions
A ‘net reduction in disability per 1000 patients treated’
could be reported alongside the common odds ratio
from the proportional odds model.
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